Want to see IN:VIMTALABS full AI Analyst Report?
VIMTALABS Stock Chart & Stats
₹609.25
-₹18.70(-1.83%)
At close: 4:00 PM EST
₹609.25
-₹18.70(-1.83%)
Day’s Range― - ―
52-Week Range₹377.30 - ₹902.85
Previous CloseN/A
Volume71.13K
Average Volume (3M)22.50K
Market Cap
₹26.25B
Enterprise Value₹23.68B
Total Cash (Recent Filing)₹564.64M
Total Debt (Recent Filing)₹67.97M
Price to Earnings (P/E)33.8
Beta1.07
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.16%
Share Statistics
EPS (TTM)17.65
Shares Outstanding44,669,353
10 Day Avg. Volume11,086
30 Day Avg. Volume22,501
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)3.71
Price to Sales (P/S)4.16
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)20.1
Revenue Forecast (FY)₹4.71B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNear-zero leverage and rising equity give the company durable financial flexibility to fund lab capacity, meet regulatory capital needs, and invest in specialized equipment without relying on external debt. This lowers financial risk and supports long-term contract wins in regulated markets.
Healthy Profitability And MarginsSustained mid-to-high teen net margins and mid-30% EBITDA margin reflect structural pricing power in specialized testing and CRO services. High margins support reinvestment, buffer cyclical downturns, and enable steady returns on capital across the business lifecycle.
Business Model & Revenue MomentumA fee-for-service outsourced model tied to regulated development and quality programs drives repeatable, contractable revenue. Combined with multi-year revenue growth (~16%), this indicates durable demand from pharma/biotech clients and structural tailwinds as outsourcing intensifies.
Bears Say
Margin VolatilityNotable swings in gross and operating margins—including a sharp shift from very high levels in 2023–2024 to lower in 2025–2026—reduce earnings predictability. Persistent mix or cost variability can erode long-term margin sustainability and planning for capacity investments.
Uneven Free Cash FlowInconsistent cash conversion and a prior year of negative free cash flow imply working-capital swings and timing risk in receipts vs. payouts. This can constrain organic funding for lab expansion, increase sensitivity to client payment cycles, and pressure dividend or buyback policies.
Limited ROE ExpansionWhile ROE is mid-teens (solid), the lack of meaningful expansion suggests limited operational leverage or plateauing asset returns. Over the medium term, this may cap earnings-per-share growth unless the company materially improves utilization or enters higher-margin service lines.
Vimta Labs Limited News
VIMTALABS FAQ
What was Vimta Labs Limited’s price range in the past 12 months?
Vimta Labs Limited lowest stock price was ₹377.30 and its highest was ₹902.85 in the past 12 months.
What is Vimta Labs Limited’s market cap?
Vimta Labs Limited’s market cap is ₹26.25B.
When is Vimta Labs Limited’s upcoming earnings report date?
Vimta Labs Limited’s upcoming earnings report date is Aug 14, 2026 which is in 43 days.
How were Vimta Labs Limited’s earnings last quarter?
Vimta Labs Limited released its earnings results on May 06, 2026. The company reported ₹4.726 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.726.
Is Vimta Labs Limited overvalued?
According to Wall Street analysts Vimta Labs Limited’s price is currently Overvalued.
Does Vimta Labs Limited pay dividends?
Vimta Labs Limited pays a Annually dividend of ₹2 which represents an annual dividend yield of 0.16%. See more information on Vimta Labs Limited dividends here
What is Vimta Labs Limited’s EPS estimate?
Vimta Labs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vimta Labs Limited have?
Vimta Labs Limited has 44,669,353 shares outstanding.
What happened to Vimta Labs Limited’s price movement after its last earnings report?
Vimta Labs Limited reported an EPS of ₹4.726 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.338%.
Which hedge fund is a major shareholder of Vimta Labs Limited?
Currently, no hedge funds are holding shares in IN:VIMTALABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimta Labs Limited
Vimta Labs Limited provides specialized contract research and analytical testing services, operating both within India and internationally. Their extensive offerings encompass general laboratory analyses, comprehensive food and water quality testing, support for preclinical and clinical research, detailed structural and functional assessments of biological molecules, environmental impact studies, and clinical diagnostic reference laboratory capabilities. The company serves a wide array of industries, including pharmaceuticals, biopharmaceuticals, food production, consumer goods, electronics, electrical equipment, agrochemicals, healthcare, medical devices, and many more. Established in 1984, Vimta Labs Limited is headquartered in Hyderabad, India.
Technical Analysis
Krsnaa Diagnostics Limited
―
Dr. Lal PathLabs Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―